Antidepressant therapy in complex treatment of painful diabetic polyneuropathy

Aims. Comparative efficiency and safety analysis of antidepressant agents from different pharmacological classes (pipofezine and venlafaxine)in combination with carbamazepine for treatment of neuropathic pain (NP) in patients with diabetic polyneuropathy (DP). Materials and methods. We examined 21...

Full description

Saved in:
Bibliographic Details
Main Authors: Lidia Grigor'evna Turbina, Sergey Alexandrovich Gordeev, Anna Aronovna Zus'man
Format: Article
Language:English
Published: Endocrinology Research Centre 2012-09-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/6088
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850141131961008128
author Lidia Grigor'evna Turbina
Sergey Alexandrovich Gordeev
Anna Aronovna Zus'man
author_facet Lidia Grigor'evna Turbina
Sergey Alexandrovich Gordeev
Anna Aronovna Zus'man
author_sort Lidia Grigor'evna Turbina
collection DOAJ
description Aims. Comparative efficiency and safety analysis of antidepressant agents from different pharmacological classes (pipofezine and venlafaxine)in combination with carbamazepine for treatment of neuropathic pain (NP) in patients with diabetic polyneuropathy (DP). Materials and methods. We examined 21 male and 27 female patients with painful DP (mean age 54.3?14.2 years; mean duration ofdiabetes mellitus (DM) 8.9?5.1 years; mean duration of DP - 3.8?2.1 years). DP was diagnosed clinically and by electromyographymethod. Pain syndrome was assessed with DN4 questionnaire, visual analogue scale (VAS) and McGill Pain Questionnaire. Psycho-vegetative status was evaluated by Spielberger test with reactive and personal anxiety (RA and PA) assessment and Beck depressioninventory. All patients received symptomatic pharmacotherapy with anticonvulsant and antidepressant agent. First group (DP-1)included 23 patients on carbamazepin and pipofezine. Second group (DP-2) included 25 patients on carbamazepin and venlafaxine. Results. Following treatment, pain syndrome was completely compensated in 8.7% of patients from DP-1 group and 12.5% from DP-2.Decrease in pain intensity?50% from initial level was achieved in 73.9% (DP-1) and 75% (DP-2) of cases. Mean pain intensityaccording to VAS reduced from 5.2?2.1 points to 2.3?1.4 points (DP-1) and from 5.8?2.3 points (DP-2) with equal statistical significance(p
format Article
id doaj-art-a07cf4cbcb9e484995ebefa677e678f8
institution OA Journals
issn 2072-0351
2072-0378
language English
publishDate 2012-09-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-a07cf4cbcb9e484995ebefa677e678f82025-08-20T02:29:34ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782012-09-01153677310.14341/2072-0351-60886046Antidepressant therapy in complex treatment of painful diabetic polyneuropathyLidia Grigor'evna Turbina0Sergey Alexandrovich Gordeev1Anna Aronovna Zus'man2Moscow Regional Clinical Research Institute named after Vladimirsky, Moscow, Russian FederationNeurology Research Centre, Moscow, Russian FederationMoscow Regional Clinical Research Institute named after Vladimirsky, Moscow; Moscow Tsar Clinic, MoscowAims. Comparative efficiency and safety analysis of antidepressant agents from different pharmacological classes (pipofezine and venlafaxine)in combination with carbamazepine for treatment of neuropathic pain (NP) in patients with diabetic polyneuropathy (DP). Materials and methods. We examined 21 male and 27 female patients with painful DP (mean age 54.3?14.2 years; mean duration ofdiabetes mellitus (DM) 8.9?5.1 years; mean duration of DP - 3.8?2.1 years). DP was diagnosed clinically and by electromyographymethod. Pain syndrome was assessed with DN4 questionnaire, visual analogue scale (VAS) and McGill Pain Questionnaire. Psycho-vegetative status was evaluated by Spielberger test with reactive and personal anxiety (RA and PA) assessment and Beck depressioninventory. All patients received symptomatic pharmacotherapy with anticonvulsant and antidepressant agent. First group (DP-1)included 23 patients on carbamazepin and pipofezine. Second group (DP-2) included 25 patients on carbamazepin and venlafaxine. Results. Following treatment, pain syndrome was completely compensated in 8.7% of patients from DP-1 group and 12.5% from DP-2.Decrease in pain intensity?50% from initial level was achieved in 73.9% (DP-1) and 75% (DP-2) of cases. Mean pain intensityaccording to VAS reduced from 5.2?2.1 points to 2.3?1.4 points (DP-1) and from 5.8?2.3 points (DP-2) with equal statistical significance(phttps://www.dia-endojournals.ru/jour/article/view/6088diabetic polyneuropathyneuropathic painanxietydepressionvenlafaxinepipofezinecarbamazepine
spellingShingle Lidia Grigor'evna Turbina
Sergey Alexandrovich Gordeev
Anna Aronovna Zus'man
Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
Сахарный диабет
diabetic polyneuropathy
neuropathic pain
anxiety
depression
venlafaxine
pipofezine
carbamazepine
title Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
title_full Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
title_fullStr Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
title_full_unstemmed Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
title_short Antidepressant therapy in complex treatment of painful diabetic polyneuropathy
title_sort antidepressant therapy in complex treatment of painful diabetic polyneuropathy
topic diabetic polyneuropathy
neuropathic pain
anxiety
depression
venlafaxine
pipofezine
carbamazepine
url https://www.dia-endojournals.ru/jour/article/view/6088
work_keys_str_mv AT lidiagrigorevnaturbina antidepressanttherapyincomplextreatmentofpainfuldiabeticpolyneuropathy
AT sergeyalexandrovichgordeev antidepressanttherapyincomplextreatmentofpainfuldiabeticpolyneuropathy
AT annaaronovnazusman antidepressanttherapyincomplextreatmentofpainfuldiabeticpolyneuropathy